This phase II trial is evaluating the effectiveness of an oral drug (pamiparib) in men with metastatic castration-resistant prostate cancer.
This trial is treating patients with metastatic castration-resistant prostate cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Open-Label, Single-Arm Study of BGB-290 (BGB-290) for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD)
BeiGene Australia Pty Ltd
In this trial, all enrolled patients will receive 60mg of oral pamiparib twice a day.
Recruiting Hospitals Read More